

## Key Word Index

---

### A

aCGH 49:500  
 acrocentric rearrangement 49:62  
 acute fatty liver of pregnancy 49:156  
 adenomyosis 49:40, 160  
 aerobic exercise 49:432  
 Alzheimer's disease 49:468  
 amniocentesis 49:62, 333, 341, 455  
 amniotic fluid cells 49:139  
 amniotic fluid-derived stem cells 49:139  
 antenatal serum screening 49:50  
 anti-proliferation 49:266  
 aortic cross-clamping 49:72  
 apoptosis 49:174  
 array comparative genomic hybridization 49:327  
 arsenic 49:449  
 assisted reproduction 49:302  
 assisted reproductive technologies 49:199  
 atosiban 49:495  
 awareness 49:306

### B

balanced reciprocal translocation 49:455  
 benomyl 49:449  
 biochemical markers 49:3  
 birth trauma 49:170  
 birth weight estimation 49:285  
 Bishop score 49:57  
 blastocyst 49:174  
 blastocyst transfer 49:35  
 blood loss 49:72

### C

caffeic acid 49:266, 419  
 carbendazim 49:449  
 carcinosarcoma 49:87  
 cellular 49:203  
 cerebrovascular disease 49:395  
 cervical cancer 49:407  
 cervical cancer cell line 49:266, 419  
 cesarean 49:254  
 cesarean hysterectomy 49:72  
 cesarean section 49:425  
 chemotherapy 49:69  
 chromosome 1 49:473  
 chromosome 13 49:320  
 chromosome 16 49:506  
 chromosome 17 49:188  
 chromosome 18 49:188  
 chromosome 1p36 deletion syndrome 49:473  
 chromosome 20 49:473  
 chromosome 22 49:506  
 chromosome 7 49:320  
 chromosome 8 49:500

clavicle fracture 49:170  
 cleavage-stage embryo 49:35  
 combined screening test 49:145  
 confined placental mosaicism 49:13  
 congenital diarrhea 49:487  
 congenital heart defects 49:81  
 congenital infection 49:206  
 congenital malformations 49:3  
 controlled ovarian hyperstimulation 49:297  
 couple relationship 49:407  
 C-reactive protein 49:181  
 cryopreservation 49:272  
 cutaneous T-cell lymphoma 49:69  
 cytochrome c 49:419  
 cytomegalovirus 49:206

### D

Dandy-Walker malformation 49:320  
 dinoprostone 49:151  
 disseminated intravascular coagulation 49:156  
 DNA 49:206  
 Down syndrome 49:30, 50, 62  
 ductus venosus 49:145

### E

Ellis-van Creveld syndrome 49:481  
 embryo morphology 49:35  
 embryo quality 49:302  
 embryonic development 49:174  
 en caul 49:254  
 encephalopathy 49:77  
 endometrial ablation 49:311  
 endometrial cancer 49:401  
 endometrioma 49:45  
 endometrium 49:449  
 epicatechin gallate 49:174  
 epigenetics 49:468  
 EPPROM 49:495  
 estrogen 49:413  
 estrogen-progestin 49:413  
 ethical problems 49:291  
 EVC 49:481  
 EVC2 49:481  
 expulsion 49:160

### F

fetal ascites 49:206, 506  
 fetal biometrics 49:285  
 fetal death 49:156  
 fetal injuries 49:170  
 fetus 49:23, 133  
 fistula campaign 49:291  
 flow-cytometry 49:419  
 fluorescence *in situ* hybridization 49:327  
 folic acid 49:306

|  |             |  |                                      |
|--|-------------|--|--------------------------------------|
| follicular cyst                              | 49:45       | medical ethics                             | 49:50                                |
| follicular size                              | 49:302      | medical induction                          | 49:438                               |
| forensic medicine                            | 49:165      | membranes                                  | 49:254                               |
| frozen section                               | 49:203      | menorrhagia                                | 49:160                               |
| <b>G</b>                                     |             | metabolic syndrome                         | 49:432                               |
| gene therapy                                 | 49:23       | methylene blue                             | 49:77                                |
| genital/anal injury                          | 49:165      | microcephaly                               | 49:320                               |
| GnRH agonist                                 | 49:297      | microvillus inclusion disease              | 49:487                               |
| GnRH antagonist                              | 49:297      | midtrimester pregnancy                     | 49:438                               |
| gonadal dysgenesis                           | 49:199      | Miller-Dieker syndrome                     | 49:81                                |
| gonadotropin                                 | 49:442      | Mirena                                     | 49:160                               |
| <b>H</b>                                     |             | misoprostol                                | 49:151, 438                          |
| heterologous Robertsonian translocations     | 49:62       | MLPA                                       | 49:500                               |
| high performance liquid chromatography       | 49:266      | monosomy 13q                               | 49:320                               |
| high-sensitivity                             | 49:181      | monosomy 17p                               | 49:81                                |
| hormone therapy                              | 49:413      | monosomy 1p36                              | 49:473                               |
| human cleavage-stage embryo                  | 49:272      | monosomy 22q                               | 49:506                               |
| human papillomavirus                         | 49:407      | mosaic ring chromosome                     | 49:327                               |
| hypoglycemia                                 | 49:156      | mosaic trisomy 7                           | 49:333                               |
| hysteroscopy                                 | 49:311      | mosaic trisomy 9                           | 49:341                               |
| <b>I</b>                                     |             | mosaicism                                  | 49:13, 333, 341                      |
| ifosfamide                                   | 49:77       | MYOSB                                      | 49:487                               |
| <i>in situ</i> morcellation                  | 49:279      | <b>N</b>                                   |                                      |
| <i>in vitro</i> fertilization                | 49:297      | neurotoxicity thiamine                     | 49:77                                |
| induction                                    | 49:151      | nuchal translucency                        | 49:133                               |
| informed consent                             | 49:50       | <b>O</b>                                   |                                      |
| injection                                    | 49:23       | obstetric fistula                          | 49:291                               |
| insomnia                                     | 49:468      | oocytes                                    | 49:302                               |
| instrumental delivery                        | 49:170      | operative complications                    | 49:425                               |
| intracytoplasmic                             | 49:302      | orexin                                     | 49:468                               |
| intrauterine growth restriction              | 49:81       | ovarian failure                            | 49:69                                |
| <b>L</b>                                     |             | ovary                                      | 49:87                                |
| labor  | 49:151      | oxytocin                                   | 49:57                                |
| labor induction                              | 49:57       | <b>P</b>                                   |                                      |
| laparoscopic myomectomy                      | 49:279      | pathophysiology                            | 49:133                               |
| laparoscopic staging surgery                 | 49:401      | phylloid hypomelanosis                     | 49:13                                |
| large myomas                                 | 49:279      | picture archiving and communication system | 49:45                                |
| leiomyoma                                    | 49:203, 247 | placenta accreta                           | 49:197                               |
| letrozole                                    | 49:297      | placenta percreta                          | 49:72                                |
| levonorgestrel-releasing intrauterine system | 49:160      | polymorphism                               | 49:247                               |
| linear striation                             | 49:40       | poor ovarian reserve                       | 49:442                               |
| lipid  | 49:181      | poor responder                             | 49:442                               |
| lissencephaly                                | 49:81       | poor responders                            | 49:297                               |
| low calorie diet                             | 49:432      | postmenopausal women                       | 49:413                               |
| lower urinary tract symptoms                 | 49:260      | postpartum hemorrhage                      | 49:197                               |
| <b>M</b>                                     |             | preeclampsia                               | 49:181, 254                          |
| malignant mixed müllerian tumor              | 49:87       | pregnancy                                  | 49:181, 192, 197, 306, 311, 395, 442 |
| mammographic density                         | 49:413      | pregnancy interval                         | 49:285                               |
| marker chromosome 18                         | 49:188      | premature labor                            | 49:192                               |
| mastocytosis                                 | 49:192      | premature rupture of membranes             | 49:57                                |
| maternal body mass index                     | 49:285      |  |                                      |
| Mayer-Rokitansky-Küster-Hauser syndrome      | 49:69       |  |                                      |

|                    |   |
|--------------------|---|
| prenatal diagnosis | 49:3, 13, 188,<br>206, 327, 473,<br>481, 487, 500 |
| preterm labor      | 49:254  |
| prostaglandin E2   | 49:57   |
| puerperium         | 49:395  |

## Q

|                |       |
|----------------|-------|
| quadruple test | 49:30 |
|----------------|-------|

## R

|   |        |
|---|--------|
| reciprocal translocation                | 49:188 |
| renal failure                           | 49:156 |
| ring chromosome 18 duplication/deletion | 49:327 |
| risk factors                            | 49:260 |
| robotic surgery                         | 49:401 |
| round-cell tumor                        | 49:203 |

## S

|                                       |             |
|---------------------------------------|-------------|
| second trimester                      | 49:30       |
| selenium                              | 49:181      |
| sex ratio                             | 49:35       |
| sexual assault                        | 49:165      |
| sexual life                           | 49:407      |
| sheep                                 | 49:23       |
| side population                       | 49:139      |
| SKY                                   | 49:500      |
| slow freezing                         | 49:272      |
| small supernumerary marker chromosome | 49:188, 500 |
| sperm injection                       | 49:302      |
| standard deviation                    | 49:45       |
| stomach                               | 49:23       |
| stroke                                | 49:395      |
| supplementation                       | 49:306      |
| surgical outcomes                     | 49:401      |

## T

|                               |          |
|-------------------------------|----------|
| therapeutic lifestyle program | 49:432   |
| transvaginal sonography       | 49:40    |
| trauma                        | 49:165   |
| tricuspid regurgitation       | 49:145   |
| trisomy 13                    | 49:3, 13 |
| trisomy 16p                   | 49:506   |
| trisomy 21                    | 49:62    |
| trisomy 7                     | 49:333   |
| trisomy 7p                    | 49:320   |
| trisomy 9                     | 49:341   |
| tumor density                 | 49:45    |
| twin pregnancy                | 49:495   |

## U

|                                     |                                     |
|-------------------------------------|-------------------------------------|
| ultrasound                          | 49:3, 23, 45, 285,<br>473, 481, 487 |
| uniparental disomy                  | 49:62                               |
| uniparental disomy for chromosome 7 | 49:333                              |
| uniparental disomy for chromosome 9 | 49:341                              |
| urgent and elective cases           | 49:425                              |
| urinary frequency                   | 49:260                              |
| uterine artery embolization         | 49:197                              |
| uterine myoma                       | 49:197                              |

## V

|                                    |            |
|------------------------------------|------------|
| vascular endothelial growth factor | 49:247     |
| ventriculomegaly                   | 49:81, 506 |
| vitrification                      | 49:272     |

## W

|                |        |
|----------------|--------|
| weight control | 49:432 |
|----------------|--------|

## Y

|                 |        |
|-----------------|--------|
| Y microdeletion | 49:199 |
|-----------------|--------|